Evaluation of serum osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in obese and non-obese patients with polycystic ovary syndrome

Esra Tutal1, Mıyesser Saykı Arslan1, Melia Karaköse1, Taner Demirci1, Erman Çakal1, Mustafa Özbek1, Mustafa Şahin2, Gönül Erden3, Tuncay Delibaş4

1Dışkapı Yıldırım Beyazıt Teaching and Research Hospital, Ankara, Turkey
2Ankara University, School of Medicine, Ankara, Turkey

Introduction

Polycystic ovary syndrome (PCOS) is a common endocrinopathy associated with increased cardiovascular risk in reproductive aged women. Circulating osteoprotegerin (OPG) and soluble receptor activator of nuclear factor κB ligand (sRANKL) are associated with subclinical atherosclerosis. Our aim is to evaluate serum OPG and sRANKL levels and their relations with cardiovascular and metabolic markers in patients with obese and non-obese PCOS.

Methods

Overall 25 patients with PCOS (14 obese, 11 non-obese, group 1 and group 2, respectively) and 27 age matched controls (group 3) recruited to the study. Metabolic and hormonal profiles, carotid artery intima-media thickness (CIMT), serum OPG and sRANKL levels were assessed.

Results

Mean OPG and sRANKL levels were similar between three groups (p>0.05). Serum HDL levels were similar in group 1 and 2, but significantly different in group 2 and 3, group 1 and 3 (p=0.4, p=0.04, p=0.001 respectively). Serum total testosterone levels were similar in group 1 and 2, group 1 and 3 but significantly different in group 2 and 3 (p=0.11, p=0.31, p=0.02 respectively). Homeostasis model assessment-insulin resistance was similar in group 2 and 3, whereas different in group 1 and 3, group 1 and 2 (p= 0.7, p=0.001, p=0.001 respectively). hsCRP levels were significantly higher in group 1 than in group 2 (p=0.04). However, CIMT measurements were similar in three groups. Furthermore, no significant correlation between OPG, sRANKL and cardiovascular and metabolic parameters.

Conclusions

PCOS is associated with increased cardiovascular risk particularly in obese patients. Based on the results of this study, OPG and sRANKL had not taken a critical role on the development of preclinical atherosclerosis in PCOS. Further prospective studies are needed in large number of patients on this issue.